#JPM20: 'The NPV is al­ways wrong.' Take­da preps an­oth­er spin­out — this time on psych

Ed­i­tor’s Note: End­points News is re­port­ing live from #JPM20 af­ter kick­ing things off with an ac­tion-packed event, which you can re­play here. What fol­lows is a stream of tid­bits we have col­lect­ed while wan­der­ing around Union Square in San Fran­cis­co. Check back in through­out the week for up­dates by John Car­roll and Ja­son Mast.

SAN FRAN­CIS­CO — A year ago Take­da CEO Christophe We­ber and R&D chief Andy Plump ar­rived at JP Mor­gan right on the heels of clos­ing their big Shire buy­out. Now they’re back af­ter shak­ing up the port­fo­lio, boost­ing R&D spend­ing by about 50% to $4.5 bil­lion and ad­just­ing the pipeline — a task which isn’t quite fin­ished yet.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER